Dermatology News and Research

Latest Dermatology News and Research

Valeant signs agreement to acquire iNova

Valeant Pharmaceuticals International, Inc. announced today that it has signed an agreement to acquire iNova, a private pharmaceutical group which sells and distributes a range of prescription and over-the-counter (OTC) products in Australia, New Zealand, Southeast Asia and South Africa from Archer Capital, Ironbridge and other minority management shareholders.

21 Nov 2011

Psoriasis may alter cholesterol composition and decrease HDL function

Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.

17 Nov 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

A recent study led by researchers at Boston University School of Medicine (BUSM) shows an increased risk of stroke and mortality among patients diagnosed with severe sepsis and new-onset atrial fibrillation (AF) during hospitalization.

14 Nov 2011

Novel gene mutation may increase risk of inherited and sporadic cases of MM

A major international study has identified a novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer.

14 Nov 2011

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

80% of Melbourne tanning salons allow underage customers

According to a recent survey by the Cancer Council Victoria, solarium operators are flouting rules by allowing teenagers under 18 to use sun beds despite laws banning them from doing so.

8 Nov 2011

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

7 Nov 2011

Avoiding sun may increase risk of vitamin D deficiency in light-skinned people

Light-skinned people who avoid the sun are twice as likely to suffer from vitamin D deficiency as those who do not, according to a study of nearly 6,000 people by researchers at the Stanford University School of Medicine.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Study: Melanoma survivors more likely to have new cancers

Melanoma skin cancer survivors are much more likely than the general population to have future new cases of invasive melanomas and other cancers, says a national study led by UAMS' Appathurai Balamurugan, M.D., M.P.H.

3 Nov 2011

Internet-based communication improves teenagers' use of topical acne therapy

Tech-savvy teens with acne used their medicine more frequently when they also took part in a web-based survey, a new study from Wake Forest Baptist Medical Center finds.

1 Nov 2011

Wintertime skin care tips

Winter time woes extend beyond cold temperatures and sometimes gloomy weather. Your skin can react to the constant temperature changes as you move indoor to outdoor for daily living activities. Rita Pichardo-Geisinger, M.D., of the Wake Forest Baptist Medical Center dermatology department, is part of an internationally renowned team of clinicians who provide clinical care for patients. Pichardo-Geisinger provides these tips that are easy to incorporate into your daily routine to help keep your skin and hair in prime condition.

29 Oct 2011

Henry Ford becomes first U.S. hospital to offer skin transplant surgery for vitiligo

Henry Ford Hospital is the first in the country to offer skin transplant surgery as part of its treatment portfolio for patients with the skin disease vitiligo.

27 Oct 2011

Coffee may protect against a slow growing skin cancer: Study

A new study shows that drinking coffee was associated with decreased risk of a common and slow-growing form of skin cancer called basal cell carcinoma.

25 Oct 2011

Merz presents XEOMIN clinical data on dystonia at IDS 2011

New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.

22 Oct 2011

State roundup: Md. program poised for health reform; Calif. high-risk pool; huge insurance premium jump in La. district

Its accountable care organizations will be called coordinated care organizations. And, instead of just aiming to cut costs and increase the quality of care, Oregon wants to actually grade them.

21 Oct 2011

IRIDEX introduces optional MicroPulse module

IRIDEX Corporation announced today that it has expanded its product offering by introducing an optional MicroPulse module in the Company's IQ532 (green) laser system and now provides a complete portfolio of infrared, yellow and green laser systems which can deliver MicroPulse laser treatments.

19 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

GeneDx launches new genetic test to accurately diagnose rare diseases

At the joint conference of the American Society of Human Genetics/International Congress on Human Genetics in Montreal on October 12, GeneDx, one of the foremost genetics laboratories in the world and a subsidiary of Bio-Reference Laboratories, Inc., is announcing a first-of-its-kind test that will enable physicians and patients to more accurately identify the genetic cause of rare diseases.

13 Oct 2011